Study Stopped
COVID emergency
Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder
VR4FND
Safety and Feasibility of Virtual Reality Therapy for Functional Neurological Symptom/Conversion Disorder
1 other identifier
interventional
15
1 country
1
Brief Summary
The purpose of this study is to design and test the safety and feasibility of virtual reality technologies and experiences of egocentric avatar embodiment in the application of physical and cognitive behavior therapy in functional neurological symptom/conversion disorder. Investigators hypothesize that patients will safely use and accept this modality of treatment and will show evidence of a decrease in symptom frequency.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2016
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2016
CompletedFirst Submitted
Initial submission to the registry
May 2, 2016
CompletedFirst Posted
Study publicly available on registry
May 6, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedAugust 30, 2023
August 1, 2023
5.6 years
May 2, 2016
August 28, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Adherence
Number of sessions attended over 12 weeks recorded by therapist
Number of sessions attended over 12 weeks
Secondary Outcomes (7)
General Self-Efficacy Scale
baseline, biweekly for 6weeks, then 6,9,12 months
Global Assessment of Functioning (GAF)
baseline, 6weeks, then 6,9,12 months
Generalized Anxiety Disorder 7-item (GAD-7) scale
baseline, biweekly for 6weeks then 6,9,12 months
Patient Health Questionnaire-9 (PHQ-9)
baseline, biweekly for 6weeks then 6,9,12 months
Oxford Handicap Scale
baseline, 6weeks, then 6,9,12 months
- +2 more secondary outcomes
Study Arms (2)
Virtual Reality Therapy
EXPERIMENTALEight 30 minute sessions of embodied virtual reality therapy with use of a body transfer experience into an egocentric perspective avatar that encourages motor activity and desensitization to emotional cues.
Control
ACTIVE COMPARATOREight 30 minute sessions of virtual reality therapy.
Interventions
Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
Eligibility Criteria
You may qualify if:
- Adults 18-65 years, who are diagnosed with functional neurologic symptom or conversion disorder. If diagnosis of seizure type then video EEG with diagnosis confirmed by board-certified neurologist with subspecialty training in epilepsy and clinical neurophysiology using the criteria of the International Classification of the Epilepsies is required. If diagnosis of motor type, documented and clinically established levels of diagnostic certainty (Williams,1995) confirmed by 2 neurologists is required.
- Participants must have at least one symptom per month in the month prior to enrollment
- Fluency in English spoken language
You may not qualify if:
- Nonfluency or inability to communicate in English spoken language
- Inability to participate or attend biweekly 30 minute session over 14 weeks
- Frank psychosis
- Active self harm urges
- Serious medical illness
- Active substance or alcohol use or dependence that could interfere with participation
- Diagnoses of mental retardation, dementia or delirium
- Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stanford University
Stanford, California, 94010, United States
Related Publications (1)
Bullock K, Won AS, Bailenson J, Friedman R. Virtual Reality-Delivered Mirror Visual Feedback and Exposure Therapy for FND: A Midpoint Report of a Randomized Controlled Feasibility Study. J Neuropsychiatry Clin Neurosci. 2020 Winter;32(1):90-94. doi: 10.1176/appi.neuropsych.19030071. Epub 2019 Nov 5.
PMID: 31687867RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kim D Bullock, MD
Stanford University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Associate Professor
Study Record Dates
First Submitted
May 2, 2016
First Posted
May 6, 2016
Study Start
May 1, 2016
Primary Completion
December 1, 2021
Study Completion
December 1, 2021
Last Updated
August 30, 2023
Record last verified: 2023-08
Data Sharing
- IPD Sharing
- Will not share